Indication

For adult patients with relapsing remitting multiple sclerosis.

Medicine details

Medicine name:
ozanimod (Zeposia)
SMC ID:
SMC2309
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
08 February 2021
SMC meeting date:
12 January 2021
Patient group submission deadline:
30 November 2020